Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Average Rating of “Moderate Buy” by Analysts

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) have been given an average rating of “Moderate Buy” by the six brokerages that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $20.60.

Several research analysts have issued reports on the company. Piper Sandler reaffirmed an “overweight” rating and set a $12.00 price objective (down previously from $15.00) on shares of Karyopharm Therapeutics in a report on Thursday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Karyopharm Therapeutics in a report on Wednesday. Robert W. Baird reduced their price objective on Karyopharm Therapeutics from $25.00 to $21.00 and set an “outperform” rating on the stock in a report on Thursday. Finally, HC Wainwright downgraded Karyopharm Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday, July 16th.

Karyopharm Therapeutics Stock Performance

NASDAQ:KPTI opened at $5.82 on Friday. The stock’s fifty day moving average price is $5.97 and its two-hundred day moving average price is $5.16. Karyopharm Therapeutics has a 52-week low of $3.51 and a 52-week high of $16.95. The company has a market cap of $50.46 million, a price-to-earnings ratio of -0.40 and a beta of 0.34.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings data on Monday, August 11th. The company reported ($4.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.80) by ($0.52). The business had revenue of $37.93 million during the quarter, compared to analysts’ expectations of $37.92 million. Karyopharm Therapeutics has set its FY 2025 guidance at EPS. On average, equities analysts predict that Karyopharm Therapeutics will post -0.71 EPS for the current fiscal year.

Institutional Trading of Karyopharm Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in KPTI. Baird Financial Group Inc. bought a new stake in shares of Karyopharm Therapeutics during the 2nd quarter valued at $45,000. XTX Topco Ltd bought a new stake in shares of Karyopharm Therapeutics during the 2nd quarter valued at $56,000. Two Sigma Investments LP raised its position in shares of Karyopharm Therapeutics by 60.3% during the 4th quarter. Two Sigma Investments LP now owns 137,786 shares of the company’s stock valued at $93,000 after acquiring an additional 51,856 shares during the last quarter. Bridgeway Capital Management LLC bought a new stake in shares of Karyopharm Therapeutics during the 2nd quarter valued at $163,000. Finally, Silverback Asset Management LLC raised its position in shares of Karyopharm Therapeutics by 40.0% during the 2nd quarter. Silverback Asset Management LLC now owns 70,000 shares of the company’s stock valued at $302,000 after acquiring an additional 20,000 shares during the last quarter. Institutional investors own 66.44% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).